Trust Co. of Oklahoma Boosts Stake in Eli Lilly and Company (NYSE:LLY)

Trust Co. of Oklahoma lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 7.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 525 shares of the company’s stock after acquiring an additional 36 shares during the quarter. Trust Co. of Oklahoma’s holdings in Eli Lilly and Company were worth $405,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Avior Wealth Management LLC increased its holdings in Eli Lilly and Company by 8.6% in the 4th quarter. Avior Wealth Management LLC now owns 5,253 shares of the company’s stock valued at $4,056,000 after purchasing an additional 414 shares during the last quarter. Beacon Investment Advisory Services Inc. boosted its position in shares of Eli Lilly and Company by 41.0% during the fourth quarter. Beacon Investment Advisory Services Inc. now owns 28,122 shares of the company’s stock worth $21,710,000 after buying an additional 8,172 shares during the period. Peterson Wealth Advisors LLC grew its stake in shares of Eli Lilly and Company by 12.2% in the fourth quarter. Peterson Wealth Advisors LLC now owns 803 shares of the company’s stock valued at $628,000 after buying an additional 87 shares in the last quarter. MinichMacGregor Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 25.3% in the 4th quarter. MinichMacGregor Wealth Management LLC now owns 915 shares of the company’s stock valued at $707,000 after buying an additional 185 shares during the period. Finally, Raleigh Capital Management Inc. lifted its stake in Eli Lilly and Company by 14.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,295 shares of the company’s stock worth $1,000,000 after acquiring an additional 159 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 2.4 %

Eli Lilly and Company stock opened at $784.78 on Friday. The company has a market capitalization of $745.01 billion, a P/E ratio of 84.84, a PEG ratio of 1.59 and a beta of 0.41. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. Eli Lilly and Company has a fifty-two week low of $624.68 and a fifty-two week high of $972.53. The stock has a 50-day simple moving average of $776.69 and a 200-day simple moving average of $849.41.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The firm had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. Eli Lilly and Company’s quarterly revenue was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.10 EPS. Equities research analysts expect that Eli Lilly and Company will post 12.98 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be given a dividend of $1.50 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.76%. The ex-dividend date is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Eli Lilly and Company declared that its Board of Directors has initiated a stock repurchase plan on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Analyst Ratings Changes

Several research firms have weighed in on LLY. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday. Sanford C. Bernstein began coverage on shares of Eli Lilly and Company in a research note on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 target price on the stock. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Barclays cut their price objective on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. Finally, Citigroup lifted their target price on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a report on Friday, October 25th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,002.22.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.